MedTrace Logo

The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

NCT00163059 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2006-09-22

No results posted yet for this study

Summary

To determine if the NMDA antagonist, CP-101,606, is effective for depression

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

NMDA Antagonist, CP-101,606 (traxoprodil)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Completion
2005-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00163059 on ClinicalTrials.gov